Venture Capital

In a fierce biotech talent war, Senti Bio's new equity grant for a key hire signals a strategic push for its gene therapy pipeline amid market volatility.

The sustainable materials firm saw net income jump 60% after a planned shutdown created a record backlog, setting the stage for a strong Q3.

WhiteFiber lands a 10-year, 40 MW anchor deal with AI provider Nscale, validating its high-density strategy and fueling North Carolina's tech boom.

A new oral drug, cadisegliatin, enters a major clinical trial in the UAE, aiming to help Type 2 diabetes patients struggling with insulin therapy.

Facing a critical cash shortfall, Cue Biopharma turns to the market, betting its promising cancer and autoimmune pipeline can win over investors.

An executive order accelerates moving cannabis to Schedule III, promising massive tax breaks for businesses but leaving advocates wanting more federal reform.

A Minnesota startup has secured major funding to advance its bioelectronic device aimed at the brain's waste clearance system for treating CNS disorders.

With a fresh $1.5M, Katalist aims to automate video production from script to screen. But can its AI truly replace traditional workflows and empower storytellers?

In a strategic move, industry leader Ashish Malik joins DunhamTrimmer's leadership, set to guide the firm's dominance in the booming biologicals market.

Eight top US students will join a fully funded internship in Copenhagen to learn from Denmark's world-class sustainability, forging a new path for green careers.

As digital mental health fails to deliver, employers are turning to curated networks of elite, in-person practices for deeper, more specialized care.

Kitron has secured a major €44 million order for critical energy components, highlighting its key role in powering the explosive growth of AI-driven data centers.

Formerly a green housing developer, the company is now RenX Enterprises, betting its future on the multi-billion dollar market for sustainable soils.

The AI defense firm's stock surged after announcing a share repurchase, a move reflecting deep internal confidence amid a booming defense-tech market.

Picard Medical rings the NYSE bell, but its stock's volatile journey reflects the high-stakes gamble on its next-generation artificial heart technology.

The biotech upstart will present a bold pipeline, including a head-to-head trial against a market leader and a first-in-class autoimmune eye disease therapy.

Newly public AI firm Fusemachines unveils an ambitious 2026 growth plan, but faces significant financial hurdles and deep investor skepticism.

Leveraging a fleet of vintage F-104 jets, Starfighters Space raises $40M and goes public, aiming to disrupt the small satellite launch market.

An eight-figure deal for Redwire's docking systems is set to equip The Exploration Company's Nyx capsule, marking a key step for European space autonomy.

The neuro-focused biotech just acquired a late-stage cancer drug, securing massive funding. Is this a brilliant diversification or a high-stakes gamble?